TNGX
$25.60
$-0.05 (-0.19%)-0.19%
After HoursLoading chart...
IndexN/A
Market Cap4.17B
Enterprise Value0.95B
Income$-0.04B
Sales$0.01B
EmployeesN/A
P/E-30.84
P/S16.50
P/B2.97
P/C-7.36
EV/EBITDA-9.57
EV/SalesN/A
EPS (ttm)-0.83
EarningsN/A
Gross Margin96.34%
Oper. Margin-178.39%
Profit Margin-162.85%
Volume1.44M
Shs Outstand0.16B
Change-0.19%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | $24.65M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.63M | $32.27M |
| Gross Profit | $42.07M | $36.53M | $24.86M | $37.04M | $6.03M | $-7.63M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 78.77% | -30.93% |
| Operating Expenses | $187.66M | $150.70M | $135.93M | $95.23M | $58.23M | $7.54M |
| Operating Income | $-145.59M | $-114.17M | $-111.07M | $-58.19M | $-52.20M | $-15.16M |
| Operating Margin | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Net Income | $-130.30M | $-101.74M | $-108.18M | $-58.23M | $-51.97M | $-14.10M |
| Net Margin | -309.73% | -278.54% | -435.14% | -157.21% | -678.84% | -57.18% |
| EPS (Basic) | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.62 | $-1.57 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $316.49M | $402.57M | $436.47M | $500.15M | $207.25M | $55.76M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $116.97M | $149.46M | $186.99M | $155.41M | $168.65M | $47.86M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $199.52M | $253.11M | $249.48M | $344.75M | $38.60M | $7.91M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $199.52M | $253.11M | $249.48M | $344.75M | $38.60M | $7.91M |
| Total Liabilities & Stockholders Equity | $316.49M | $402.57M | $436.47M | $500.15M | $207.25M | $55.76M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-130.30M | $-101.74M | $-108.18M | $-58.23M | $-51.97M | $-14.10M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-131.50M | $-117.98M | $-109.08M | $-59.53M | $70.07M | $-24.80M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Tango Therapeutics Announces Executive Chair TransitionGlobeNewswire Inc. Tango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingGlobeNewswire Inc. Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%The Motley Fool Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million MoreThe Motley Fool The Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyGlobeNewswire Inc. Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC FilingThe Motley Fool Tango Therapeutics Appoints Sung Lee to Board of DirectorsGlobeNewswire Inc.
Show 12 more stories
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceGlobeNewswire Inc. Tango (TNGX) Q2 Revenue Drops 52%The Motley Fool Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerGlobeNewswire Inc. Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewswire Inc. Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire Inc. Barbara Weber, M.D., Elected to ITM Supervisory BoardGlobeNewswire Inc. Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?Zacks Investment Research Forecasting The Future: 4 Analyst Projections For Tango TherapeuticsBenzinga Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Discover more
You may be interested in